SCHEMBL14965845

SCHEMBL14965845

Fc1cccc(-c2csc3ncnc(Cl)c23)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.70
LMNA P02545 4/20 0.70
ALDH1A1 P00352 1/20 0.70
HTT P42858 6/20 0.61
MAPT P10636 4/20 0.61
KMT2A Q03164 3/20 0.61
PIP4K2C Q8TBX8 4/20 0.55
MITF O75030 1/20 0.55
PAX8 Q06710 1/20 0.55
NPSR1 Q6W5P4 1/20 0.54
FGFR1 P11362 4/20 0.47
DAPK3 O43293 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
ABL1 P00519 1/20 0.47
NTRK1 P04629 1/20 0.47
LCK P06239 1/20 0.47
CSF1R P07333 1/20 0.47
RET P07949 1/20 0.47
MET P08581 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1604911 0.82 SMN1; SMN2 (1.00) SMN1; SMN2LMNAALDH1A1HTTMAPT
SCHEMBL2368374 0.82 SMN1; SMN2 (0.77) SMN1; SMN2LMNAALDH1A1HTTMAPT
SCHEMBL899689 0.78 PIP4K2C (0.66) HTTPIP4K2CPAX8
SCHEMBL2369317 0.76 MAPT (1.00) SMN1; SMN2LMNAALDH1A1HTTMAPT
SCHEMBL3163635 0.76 SMN1; SMN2 (0.77) SMN1; SMN2LMNAALDH1A1HTTMAPT
SCHEMBL2368934 0.76 SMN1; SMN2 (0.67) SMN1; SMN2LMNAALDH1A1HTTMAPT
SCHEMBL3172510 0.76 SMN1; SMN2 (0.62) SMN1; SMN2LMNAALDH1A1HTTMAPT
SCHEMBL5322211 0.75 ALDH1A1 (0.64) SMN1; SMN2LMNAALDH1A1HTTMAPT
SCHEMBL3977050 0.74 SMN1; SMN2 (0.55) SMN1; SMN2LMNAALDH1A1HTTMAPT
SCHEMBL2369140 0.74 SMN1; SMN2 (1.00) SMN1; SMN2LMNAALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160152634-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2016-06-02 US disclosed
US-9290511-B2 Thieno-pyrimidines, useful as potassium channel inhibitors XENTION LIMITED (GB) 2016-03-22 US disclosed
US-20140371203-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors XENTION LIMITED (GB) 2014-12-18 US disclosed
EP-2780343-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2014-09-24 EP disclosed
WO-2013072694-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS XENTION LIMITED (GB) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371203-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors KCNA3, KCNJ1, KCNJ11 SMN1; SMN2 3639/4885LMNA 3153/4885ALDH1A1 1630/4885
US-20160152634-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS KCNA3, KCNJ1, KCNJ11 SMN1; SMN2 3669/4885LMNA 3254/4885ALDH1A1 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.